Alnylam Submits a Clinical Trial Authorization Application for ALN-HSD to UK Regulatory Bodies
Company Expects to Initiate a Phase 1 Study in Late 2020
Benzinga · 11小时前
Alnylam Pharmaceuticals (ALNY) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Alnylam (ALNY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks · 4天前
Biotech Bonanza - Second Half Outlook
Seeking Alpha · 6天前
Pfizer Surges On Coronavirus Vaccine Supply Deals But Is PFE Stock A Buy?
Investor's Business Daily · 07/27 15:00
The Week Ahead In Biotech: Spotlight On GW Pharma, Ultragenyx FDA Decisions, Pfizer Earnings
Biotech stocks moved lower in the week ended July 26, as the broader market weakness and sector-specific developments pressured stocks.
Benzinga · 07/26 13:55
A Top Contender in the Race for a NASH Drug Drops Out
French biotech Genfit, which had been expected to bring one of the first drugs to market to treat nonalcoholic steatohepatitis, said it is getting out of the race altogether.
Barrons.com · 07/23 15:02
Alnylam to Webcast Conference Call Discussing Second Quarter 2020 Financial Results
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the second quarter ending June 30, 2020 on Thursday, August 6, 2020, before the U.S. financial markets open.
Business Wire · 07/23 12:00
The Daily Biotech Pulse: Opko Wins CDC Contract, Novartis Lowers Guidance, Pieris Study Placed On Partial Clinical Hold
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 20)